DYN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.36%, SMA50 -9.62%, SMA200 7.21%). The stock’s 14-day RSI is 44.42 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -35.64% below its high and over 152.99% above its low. Average 10-day trading volume of 1.99 million shares is below the 3-month average of 2.43 million, indicating normal recent market interest.

Dyne Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.37. This means the shares are trading above this model’s fair value.

Dyne Therapeutics, Inc. (NASDAQ:DYN) closed at $16.09 USD, gaining $0.55 (3.54%) from the previous close of $15.54. The stock is currently mid-range between its 52-week high and low $6.36 and $25.00. With a market capitalization of about $2.60 billion, Dyne Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 2.45 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Dyne Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John G. Cox, the company employs approximately 192 people and listed since September 17, 2020. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.

Dyne Therapeutics, Inc. generated EPS of -$3.66 over the past year. Five-year average earnings growth is -59.45%. Wall Street analysts project EPS growth of 4.87% annually over the next five years. The latest quarter delivered EPS of -$0.76. The next quarter is forecast at -$0.76. Next year's EPS is expected at $18.82. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 13 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $9.00. The high target offers 272.9% upside. The low target suggests -44.06% downside. The mean target is $35.50. This offers 120.63% upside. Dyne Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -5.94%. The prior quarter beat by -2.02%. Over the last six quarters, Apple has recorded several small beats. These include -2.78% in August 12, 2024.

Dyne Therapeutics, Inc. has 142.26 million shares outstanding. The public float is 122.63 million shares, elevated short interest at 12.59% of float. This equals 16.04 million shares. The short ratio is 5.24 days. Institutional investors hold 95.92% of the float. Insiders own 0.49%. Kersten Dirk holds 5.40 million shares, VV Manager II, LLC has 2.88 million shares and RA CAPITAL MANAGEMENT, L.P. has 2.81 million shares. Over the past six months, insider transactions show net selling. They sold 11.79 thousand shares across 8 transactions.

Dyne Therapeutics, Inc. trades at a P/E ratio of -5.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.28 trading at moderately above to book value. The P/FCF stands at -6.53, also below market averages.

Our AI price prediction model suggests that Dyne Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.55%, with price expected at $14.07 by March 11, 2026, within a range of $13.30 to $14.90 3-Month Outlook: Projected fall of -4.41%, reaching $15.38 by May 26, 2026, with a range of $14.13 to $16.46. 1-Year Outlook: Projected gain of 7.09%, with price at $17.23 by February 25, 2027, within a range of $12.56 to $19.78.

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares are down -15.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Dyne Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.36. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $37.63, suggesting 133.87% upside. Our AI forecast model points to short-term weakness (-12.55% over two weeks), a medium-term fall (-4.41% over three months), and a longer-term gain (7.09% over one year), with expected trading ranges indicating moderate volatility.